Convalescent plasma as a treatment for high-risk outpatients administered within 7 days after COVID-19 disease onset (CoV-Early)

The CoV-Early study examines whether administering plasma from former corona patients leads to a faster recovery in corona patients who have not yet been admitted to hospital. Because previous research in the Netherlands showed no benefit from treatment with plasma at a later stage of the disease (in the hospital), we administer it quickly in this study (at the latest seven days after the onset of the disease). Research In this study, one group of patients receives plasma with antibodies and a second group, the control group, receives plasma without antibodies against the coronavirus. This is necessary to be able to reliably investigate the effectiveness of plasma. To participate, a patient must be at least 70 years old or 50 to 69 years old and also belong to a risk group. The study is coordinated by Erasmus MC and LUMC and was set up in collaboration with Sanquin. More information New corona treatment with blood plasma can start (Nov 2020) New national research into the effectiveness of antibodies in corona patients (Oct 2020) www.covearly.nl More information about research into corona and COVID-19 at www.zonmw.nl/coronaonderzoek